Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A. Mittendorf, Nadia Harbeck, Cristiano Ferrario et al.|The Lancet|2020Cited by 1.1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Seock‐Ah Im et al.|The Lancet Oncology|2018Cited by 1k
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Keiichi Fujiwara et al.|The Lancet Oncology|2021Cited by 401
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, Erica L. Mayer et al.|New England Journal of Medicine|2025Cited by 106
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) &lt; 25: SWOG S1007 (RxPonder)Kevin Kalinsky, Lajos Pusztai, William E. Barlow et al.|Cancer Research|2021Cited by 88